
PRA Health Sciences, Inc. PRAH
PRA Health Sciences, Inc. Financial Ratios 2011-2026 | PRAH
Annual Financial Ratios PRA Health Sciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E |
39.9 | 26.9 | 43.7 | 66.0 | 50.4 | 31.6 | -31.4 | - | - | - |
P/S |
2.5 | 2.1 | 2.3 | 2.5 | 1.9 | 1.6 | 0.8 | - | - | - |
EV/EBITDA |
20.8 | 15.7 | 17.8 | 20.1 | 14.9 | 13.8 | 12.9 | - | - | - |
PEG |
-2.1 | 0.47 | 0.6 | 2.74 | -2.86 | 0.12 | -0.68 | - | - | - |
P/B |
5.3 | 6.0 | 6.4 | 6.2 | 4.7 | 3.7 | 1.7 | - | - | - |
P/CF |
21.8 | 36.4 | 24.5 | 36.0 | 27.1 | 21.4 | -245.0 | - | - | - |
ROE % |
13.32 | 22.30 | 14.73 | 9.34 | 9.35 | 11.64 | -5.28 | - | - | - |
ROA % |
4.72 | 6.86 | 4.83 | 2.59 | 3.11 | 3.67 | -1.60 | - | - | - |
ROCE % |
9.75 | 14.51 | 13.87 | 11.07 | 12.79 | 9.71 | 3.21 | - | - | - |
DSO |
98.1 | 78.7 | 72.6 | 101.5 | 88.7 | 94.4 | 85.7 | - | - | - |
DPO |
9.0 | 9.2 | 7.7 | 14.8 | 14.8 | 18.5 | 13.6 | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company PRA Health Sciences, Inc., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Brainsway Ltd.
BWAY
|
$ 19.0 | 0.11 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 20.8 | 0.85 % | $ 226 M | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
$ 0.17 | -5.26 % | $ 4.99 M | ||
|
BioNano Genomics
BNGO
|
$ 1.52 | 1.2 % | $ 1.93 M | ||
|
Castle Biosciences
CSTL
|
$ 39.06 | -0.64 % | $ 1.08 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | ||
|
Danaher Corporation
DHR
|
$ 229.23 | -0.65 % | $ 168 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
DarioHealth Corp.
DRIO
|
$ 10.98 | 2.62 % | $ 312 M | ||
|
DexCom
DXCM
|
$ 66.52 | -0.81 % | $ 25.7 B | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
$ 101.86 | -0.04 % | $ 18.9 B | ||
|
Fulgent Genetics
FLGT
|
$ 26.19 | -1.13 % | $ 792 M | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
CareDx, Inc
CDNA
|
$ 18.93 | -0.73 % | $ 1.02 B | ||
|
Celcuity
CELC
|
$ 99.58 | -0.34 % | $ 3.93 B | ||
|
Anixa Biosciences
ANIX
|
$ 3.13 | 0.32 % | $ 99.8 K | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Guardant Health
GH
|
$ 102.21 | 1.6 % | $ 12.5 B | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
IQVIA Holdings
IQV
|
$ 225.57 | -0.92 % | $ 40.9 B | ||
|
ENDRA Life Sciences
NDRA
|
$ 4.45 | -6.62 % | $ 2.39 M | ||
|
Illumina
ILMN
|
$ 130.74 | -1.51 % | $ 20.8 B | ||
|
Charles River Laboratories International
CRL
|
$ 200.01 | -0.93 % | $ 10.3 B | ||
|
Koninklijke Philips N.V.
PHG
|
$ 27.17 | -0.79 % | $ 20 B | ||
|
Quidel Corporation
QDEL
|
$ 28.49 | -2.76 % | $ 1.2 B | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 173.69 | -1.03 % | $ 19.3 B | ||
|
Biodesix
BDSX
|
$ 6.75 | 0.45 % | $ 875 M | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 251.26 | -0.72 % | $ 21.1 B | ||
|
ICON Public Limited Company
ICLR
|
$ 181.71 | -0.7 % | $ 15 B | ||
|
IDEXX Laboratories
IDXX
|
$ 676.07 | -0.92 % | $ 55.8 B | ||
|
Lantheus Holdings
LNTH
|
$ 66.81 | -0.52 % | $ 4.62 B | ||
|
Mettler-Toledo International
MTD
|
$ 1 396.59 | -1.25 % | $ 29.6 B | ||
|
Agilent Technologies
A
|
$ 136.49 | -0.81 % | $ 41.5 B | ||
|
Myriad Genetics
MYGN
|
$ 6.12 | -0.89 % | $ 554 M | ||
|
Biomerica
BMRA
|
$ 2.5 | 2.04 % | $ 5.74 M | ||
|
Bioventus
BVS
|
$ 7.44 | -0.13 % | $ 466 M | ||
|
QIAGEN N.V.
QGEN
|
$ 45.03 | -0.64 % | $ 10 B | ||
|
NeoGenomics
NEO
|
$ 11.82 | -3.35 % | $ 1.5 B |